Table 1 Participant demographics and clinical characteristics
Characteristic (Units/possible range) | Mean (± SD), Median (IQR) or n (%) |
|---|---|
Number of participants | 92 |
Age (years) | 65 (± 10) |
BMI (kg/m2) | 28.8 (25.4 to 32.1) |
Female | 72 (78%) |
Ethnicity | |
White | 92 (100%) |
Self-reported Pain Severity | |
Pain – Summated (0–30) | 20 (16 to 23) |
Pain – Now (0–10) | 5 (4 to 7) |
Pain – Strongest [Last 4-weeks] (0–10) | 8 (7 to 9) |
Pain – Average [Last 4-weeks] (0–10) | 7 (5 to 8) |
Inflammation Markers | |
Bloods | |
Erythrocyte Sedimentation Rate (mm/hr) † | 21.0 (6.0 to 32.3) |
C-reactive protein (mg/l) | 5.0 (2.0 to 9.0) |
Disease Activity Score – 28 | |
DAS28 – Erythrocyte Sedimentation Rate (0-9.4) † | 4.8 (3.7 to 5.7) |
DAS28 – C-reactive protein (0-9.4) | 4.5 (3.8 to 5.2) |
Tender Joints (0–28) | 11.0 (5.0 to 15.0) |
Swollen Joints (0–28) | 3.0 (1.0 to 6.0) |
VAS Global Health (0-100) | 50.0 (30.0 to 64.0) |
D12 Tender Joints (0–12) ‡ | 5.0 (3.0 to 8.0) |
D12 Swollen Joints (0–12) ‡ | 2.0 (0.0 to 4.0) |
Tender-Swollen Difference ¥ | 6.0 (2.0 to 11.0) |
Ultrasound | |
Combined Score (0–48) | 25.5 (21.0 to 30.0) |
Synovial Hypertrophy (0–48) | 26.0 (21.0 to 30.0) |
Power Doppler (0–48) | 8.0 (4.0 to 13.0) |
D12 Combined Score (0–36) ‡ | 19.0 (16.0 to 23.0) |
D12 Synovial Hypertrophy (0–36) ‡ | 19.5 (16.0 to 23.0) |
D12 Power Doppler (0–36) ‡ | 6.5 (3.0 to 11.0) |
Quantitative Sensory Testing | |
Pain Pressure detection Threshold – Tibialis Anterior (kPa) | 236.2 (155.7 to 316.9) |
Pain Pressure detection Threshold – Brachioradialis (kPa) | 147.9 (102.7 to 215.1) |
Temporal Summation (0–10) | 1.3 (0.4 to 2.5) |
Conditioned Pain Modulation (kPa) | 63.1 (4.3 to 140.5) |
Disease Modifying Antirheumatic Drugs ø | 92 (100%) |
Methotrexate | 53 (58%) |
Sulfasalazine | 20 (22%) |
Adalimumab | 14 (15%) |
JAK Inhibitor | 8 (9%) |
Hydroxychloroquine | 6 (7%) |
Abatacept | 3 (3%) |
Etanercept | 3 (3%) |
Leflunomide | 2 (2%) |
Rituximab | 1 (1%) |
Sarilumab | 1 (1%) |
None | 0 (0%) |